Intracamaral bevacizumab in neovascular glaucoma with scleromalasia and retinal detachment

Bevacizumab treatment can reduce iris and angle neovascularisation and inhibits further PAS formation temporarily. [...]management of NVG becomes more feasible. [...]in such a rare case one can plan a special therapeutic approach: if intracamaral bevacizumab inhibits anterior segment neovascularisat...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2009, Vol.2009 (nov18 1), p.bcr0220091633-bcr0220091633
Main Author: Ciftci, Suleyman
Format: Article
Language:English
Subjects:
Cataracts
Glaucoma
Male
Medical imaging
Middle East
Retina
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
White
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab treatment can reduce iris and angle neovascularisation and inhibits further PAS formation temporarily. [...]management of NVG becomes more feasible. [...]in such a rare case one can plan a special therapeutic approach: if intracamaral bevacizumab inhibits anterior segment neovascularisation and prevent further damage of angle via inhibition of PAS, one could repeat the intracamaral injection against any reactivation of neovascularisation to maintain the patency of the meshwork and sufficient control of glaucoma without any other intervention.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr.02.2009.1633